Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.Financial_Report.xls
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R2.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R5.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R6.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R8.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R4.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R3.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R1.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R9.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R10.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R17.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R12.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R18.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R24.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R13.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R19.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R21.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R20.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R16.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R23.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R14.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R25.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R11.htm
EX-3.1 - Q Therapeutics, Inc.ex3-1.htm
EX-3.2 - Q Therapeutics, Inc.ex3-2.htm
EX-32.1 - Q Therapeutics, Inc.ex32-1.htm
EX-32.2 - Q Therapeutics, Inc.ex32-2.htm
EX-14.1 - Q Therapeutics, Inc.ex14-1.htm
EX-31.2 - Q Therapeutics, Inc.ex31-2.htm
EX-31.1 - Q Therapeutics, Inc.ex31-1.htm
10-Q - Q Therapeutics, Inc.form10q.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R7.htm
XML - IDEA: XBRL DOCUMENT - Q Therapeutics, Inc.R15.htm
v2.4.0.6
Summary of Stock Warrants Exercisable (Details) (USD $)
9 Months Ended
Sep. 30, 2012
Summary Of Stock Warrants Exercisable Details  
Common stock warrants issued for previously issued Series A2 warrants, Year of Expiration 2015
Common stock warrants issued for previously issued Series B warrants, Year of Expiration 2015
Common stock warrants issued for previously issued Series B warrants, Year of Expiration 2017
Warrants issued in conjunction with bridge notes (August 31, 2011), Year of Expiration 2018
Warrants issued in conjunction with bridge notes (August 31, 2011), Year of Expiration 2018
Warrants issued in conjunction with private placement (October 13 and December 30, 2011), Year of Expiration 2018
Warrants issued in conjunction with private placement (October 13 and December 30, 2011), Year of Expiration 2018
Warrants issued for fees in conjunction with reverse merger (October 13 and December 30, 2011), Year of Expiration 2018
Warrants issued in conjunction with private placement (February 2 and March 30, 2012), Year of Expiration 2019
Warrants issued in conjunction with private placement (February 2 and March 30, 2012), Year of Expiration 2019
Warrants issued for fees in conjunction with private placement (February 2 and March 30, 2012), Year of Expiration 2019
Warrants issued in conjunction with asset purchase agreement (April 9, 2012), Year of Expiration 2019
Warrants issued in conjunction with asset purchase agreement (April 9, 2012), Year of Expiration 2019
Common stock warrants issued for previously issued Series A2 warrants, Number of Shares 132,797
Common stock warrants issued for previously issued Series B warrants, Number of Shares 823,347
Common stock warrants issued for previously issued Series B warrants, Number of Shares 192,242
Warrants issued in conjunction with bridge notes (August 31, 2011), Number of Shares 1,816,644
Warrants issued in conjunction with bridge notes (August 31, 2011), Number of Shares 916,644
Warrants issued in conjunction with private placement (October 13 and December 30, 2011), Number of Shares 3,828,047
Warrants issued in conjunction with private placement (October 13 and December 30, 2011), Number of Shares 3,828,047
Warrants issued for fees in conjunction with reverse merger (October 13 and December 30, 2011), Number of Shares 22,750
Warrants issued in conjunction with private placement (February 2 and March 30, 2012), Number of Shares 190,000
Warrants issued in conjunction with private placement (February 2 and March 30, 2012), Number of Shares 190,000
Warrants issued for fees in conjunction with private placement (February 2 and March 30, 2012), Number of Shares 19,000
Warrants issued in conjunction with asset purchase agreement (April 9, 2012), Number of Shares 10,000
Warrants issued in conjunction with asset purchase agreement (April 9, 2012), Number of Shares 10,000
Stock warrants, exercisable, Number of Shares 11,979,518
Common stock warrants issued for previously issued Series A2 warrants, Exercise Price $ 0.046
Common stock warrants issued for previously issued Series B warrants, Exercise Price $ 1.035
Common stock warrants issued for previously issued Series B warrants, Exercise Price $ 0.532
Warrants issued in conjunction with bridge notes (August 31, 2011), Exercise Price $ 1.00
Warrants issued in conjunction with bridge notes (August 31, 2011), Exercise Price $ 2.00
Warrants issued in conjunction with private placement (October 13 and December 30, 2011), Exercise Price $ 1.00
Warrants issued in conjunction with private placement (October 13 and December 30, 2011), Exercise Price $ 2.00
Warrants issued for fees in conjunction with reverse merger (October 13 and December 30, 2011), Exercise Price $ 1.20
Warrants issued in conjunction with private placement (February 2 and March 30, 2012), Exercise Price $ 1.00
Warrants issued in conjunction with private placement (February 2 and March 30, 2012), Exercise Price $ 2.00
Warrants issued for fees in conjunction with private placement (February 2 and March 30, 2012), Exercise Price $ 1.20
Warrants issued in conjunction with asset purchase agreement (April 9, 2012), Exercise Price $ 1.00
Warrants issued in conjunction with asset purchase agreement (April 9, 2012), Exercise Price $ 2.00